Navigation Links
Smallpox Vaccine Clinical Study Now Enrolling at Avail Clinical Research near Orlando, Florida; Accepting Healthy M/F Age 18-40
Date:3/27/2013

Orlando, Florida (PRWEB) March 27, 2013

*Avail Clinical Research conducts Clinical Trials near Orlando, FL. For more information about participating in this Vaccine Clinical Trial, please visit our website or contact us directly at (386) 310-1334

BACKGROUND & SCIENTIFIC RATIONALE

Despite the fact that the World Health Organization (WHO) officially declared successful global eradication of smallpox in 1980, the existence of variola stockpiles and the threat of bioterrorism demands to maintain immunity to smallpox through vaccination.

After the events of September 11th, 2001, concern over the use of bioweapons as agents of terrorism increased. As mass vaccination programs halted more than 30 years ago, it is estimated that the majority of the world population has no existing immunity to smallpox, and as such, the release of this highly contagious virus would have devastating effects.

As a consequence, there is an urgent need for a safe and efficacious vaccine to protect the public against smallpox.

PRIMARY OBJECTIVE

-To assess the consistency of three consecutively produced IMVAMUNE® lots.

SECONDARY OBJECTIVE

-To assess uncommon adverse reactions, in particular any cardiac sign and symptom indicating a case of myo-/pericarditis, and to compare the frequency of those reactions against placebo.

-To collect vaccinia-specific humoral immune response data.

INCLUSION CRITERIA

1. Male and female subjects, 18 to 40 years of age

2. The subject has read, signed and dated the informed consent form, having been advised of the risks and benefits of the trial in a language understood by the subject and prior to performance of any trial specific procedures

3. BMI greater than/equal to 18.5 and less than 35

4. Women of childbearing potential (WOCBP) must have used an acceptable method of contraception for 30 days prior to the first vaccination, must agree to use an acceptable method of contraception during the trial, and must avoid becoming pregnant for at least 28 days after the last vaccination. A woman is considered of childbearing potential unless post-menopausal or with a history of hysterectomy (Acceptable contraception methods are restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products)

5. WOCBP must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to each vaccination

6. White blood cells greater than/equal to 2,500/mm3 and less than ULN

7. Absolute neutrophil count (ANC) within normal limits

8. Hemoglobin within normal limits

9. Platelets within normal limits

10. Adequate renal function defined as a calculated Creatinine Clearance (CrCl) greater than 60 ml/min as estimated by the Cockcroft- Gault equation

11. Adequate hepatic function

12. Troponin I less than 2 x ULN

13. Electrocardiogram (ECG) without clinically significant findings (e.g. any kind of atrioventricular or intraventricular conditions or blocks such as complete left or right bundle branch block, AV node block, QTc or PR prolongation, premature atrial contractions or other atrial arrhythmia, sustained ventricular arrhythmia, two premature ventricular contractions in a row, ST elevation consistent with ischemia)

For information about how to participate in a Vaccine Clinical Trial, visit Avail Clinical Research or contact us directly at (386) 310-1334

Read the full story at http://www.prweb.com/releases/trials/smallpox/prweb10567096.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Man Who Got Smallpox Vaccine Passes Milder Infection to Sex Partner: CDC
2. Study: Research reveals protective properties of influenza vaccines
3. TransactRx Pharmacy Vaccine Billing Provider Partners with R.J. Hedges & Associates
4. Study offers new way to discover HIV vaccine targets
5. Parents Worries About HPV Vaccine on the Rise: Study
6. Japanese P2 study shows potential of combined vaccine and steroid drug in castration-resistant PCa
7. Japanese P2 study shows potential of combined vaccine and steroid drug in castration resistant PCa
8. Chicken pox vaccine saving childrens lives
9. Prediction of seasonal flu strains improves chances of universal vaccine
10. New cancer vaccine shows future promise in treating and preventing metastatic cancers
11. H1N1 Swine Flu Vaccine Tied to Sleep Disorder in British Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... Each year Standard Process Inc. ... is this year’s Life University winner of a $2,500 scholarship from ... Leadership Awards ceremony. , Outerbridge is approaching her last quarter at Life University ...
(Date:5/26/2016)... ... ... last week’s media reports hinting at a June rate hike after the Federal Reserve’s ... interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at Georgia ... (FOMC) dot charts are of interest to the press for their noise potential,” Dhawan ...
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. Inc ., ... with a 2016 When Work Works Award for its use of effective workplace strategies ... When Work Works project administered by the Families and Work Institute (FWI) and the ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... Chicago, Illinois (PRWEB) , ... May 26, 2016 , ... ... relationship with women’s basketball as a partner for the Tamika Catchings Legacy Tour ... , As the industry leader in hardwood basketball surfaces in all forms and levels ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment of ... doses of biotin in progressive multiple sclerosis: extension phase results ... Ayman Tourbah , Principal Investigator of the Phase 3 study, ... (EAN) in Copenhagen, Denmark . The oral ... Sunday, 29 May 2016 from 14:45 to 16:15 CEST in ...
(Date:5/24/2016)... May 24, 2016   ... beide primären Endpunkte und demonstriert Ebenbürtigkeit ... ‚ausgezeichneter plus guter , ... ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... neue positive Daten von der MORA-Studie der Phase ...
Breaking Medicine Technology: